P
PetDx
Early cancer detection in dogs
About PetDx
PetDx is a startup that operates in the pet healthcare market, specifically focusing on early cancer detection in dogs. The company has developed a product called OncoK9, a multi-cancer early detection (MCED) test that uses a simple blood draw. This test is based on liquid biopsy technology, which is a non-invasive method that detects cancer by analyzing fragments of DNA released into the bloodstream by cancer cells.
Read full description
The company's primary clients are veterinarians in North America, who can order the test directly from PetDx or through its partners. The test is designed to detect cancer in its early stages, when treatment options are more effective and chances of long-term control or cure are higher. This is particularly important considering that cancer is the most common cause of death in adult dogs, with approximately 6 million new cases diagnosed each year in the United States alone.
PetDx's business model revolves around the sale of the OncoK9 test. The company generates revenue from each test sold to veterinarians. The value proposition of PetDx lies in its potential to extend the lives of dogs by enabling early detection and treatment of cancer, which could otherwise go undetected until its advanced stages.
At a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- San Diego, United States
- Employees
- 12
- Open positions
- None listed
- Dealroom signal
- 72.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning PetDx.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Dec 2021 | $62M | $248M | Valor Equity Partners · Aperture Venture Partners · Torch Capital · Friedman BioVentures | ↗ |
| FundingOther financing | Aug 2021 | $0 | — | Torch Capital | — |
Growth signals
Latest recorded traffic for PetDx is 130 monthly website visits, down 97.7% over the last three months. PetDx's team declined 7.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
Longview Asset Management
Valor Equity Partners- APAperture Venture Partners
Torch Capital- FBFriedman BioVentures
LabCorp
Declaration Partners
K4 Group
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about PetDx on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See PetDx’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.